GetTopicDetailResponse(id=14c0445e37f, topicName=奧西替尼, introduction=奧西替尼, content=null, image=null, comments=1, allHits=1782, url=https://h5.medsci.cn/topic?id=44573, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=67075, tagList=[TagDto(tagId=67075, tagName=奧西替尼)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2218586, encodeId=4b402218586e8, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a> <a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奧西替尼#</a> <a href='/topic/show?id=618511666432' target=_blank style='color:#2F92EE;'>#特泊替尼#</a>, objectTitle=Lancet子刊：廣東省人民醫(yī)院吳一龍等團(tuán)隊(duì)首次報(bào)告了特泊替尼聯(lián)合奧西替尼治療EGFR突變的非小細(xì)胞肺癌患者的最新結(jié)果！, objectType=article, longId=837318, objectId=29a283e3186d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721377358220_92910.png, objectUrl=/article/show_article.do?id=29a283e3186d, replyNumber=0, likeNumber=113, createdTime=2024-08-05, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=29a283e3186d, moduleTitle=Lancet子刊：廣東省人民醫(yī)院吳一龍等團(tuán)隊(duì)首次報(bào)告了特泊替尼聯(lián)合奧西替尼治療EGFR突變的非小細(xì)胞肺癌患者的最新結(jié)果！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=29a283e3186d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205829, encodeId=5711220582921, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a> <a href='/topic/show?id=3325955142f' target=_blank style='color:#2F92EE;'>#酪氨酸激酶抑制劑#</a> <a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奧西替尼#</a> <a href='/topic/show?id=01d411469273' target=_blank style='color:#2F92EE;'>#鐵蛋白自噬#</a>, objectTitle=Nat Commun：南京醫(yī)科大學(xué)蔣峰等團(tuán)隊(duì)合作發(fā)現(xiàn)非小細(xì)胞肺癌中鐵蛋白自噬介導(dǎo)對(duì)EGFR酪氨酸激酶抑制劑的適應(yīng)性耐藥, objectType=article, longId=826531, objectId=0b49826531ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716264487782_5579292.jpg, objectUrl=/article/show_article.do?id=0b49826531ea, replyNumber=0, likeNumber=0, createdTime=2024-05-21, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0b49826531ea, moduleTitle=Nat Commun：南京醫(yī)科大學(xué)蔣峰等團(tuán)隊(duì)合作發(fā)現(xiàn)非小細(xì)胞肺癌中鐵蛋白自噬介導(dǎo)對(duì)EGFR酪氨酸激酶抑制劑的適應(yīng)性耐藥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0b49826531ea)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183886, encodeId=991d2183886fd, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奧西替尼#</a> <a href='/topic/show?id=f46311051235' target=_blank style='color:#2F92EE;'>#埃萬(wàn)妥單抗#</a> <a href='/topic/show?id=c64a10641526' target=_blank style='color:#2F92EE;'>#拉澤替尼#</a>, objectTitle=文獻(xiàn)薦讀｜胡興勝教授：埃萬(wàn)妥單抗聯(lián)合化療或不聯(lián)合拉澤替尼治療晚期奧西替尼治療進(jìn)展后的EGFR突變NSCLC患者療效和安全性分析, objectType=article, longId=810764, objectId=cd93810e6456, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=cd93810e6456, replyNumber=0, likeNumber=132, createdTime=2024-01-25, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cd93810e6456, moduleTitle=文獻(xiàn)薦讀｜胡興勝教授：埃萬(wàn)妥單抗聯(lián)合化療或不聯(lián)合拉澤替尼治療晚期奧西替尼治療進(jìn)展后的EGFR突變NSCLC患者療效和安全性分析, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cd93810e6456)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=886724, encodeId=f798886e24c5, content=奧希替尼治療時(shí)配合適當(dāng)?shù)囊种颇退幮盘?hào)可顯著改善EGFR突變型肺癌的預(yù)后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奧西替尼#</a>, objectTitle=Nat Commun：奧希替尼配合耐藥信號(hào)抑制明顯改善EGFR突變型肺癌的預(yù)后, objectType=article, longId=200948, objectId=f9e6200948d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020919/1600508672351_2467676.PNG, objectUrl=/article/show_article.do?id=f9e6200948d3, replyNumber=0, likeNumber=152, createdTime=2020-09-19, rootId=0, userName=Nebula-Qin, userId=74c72110107, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9e6200948d3, moduleTitle=Nat Commun：奧希替尼配合耐藥信號(hào)抑制明顯改善EGFR突變型肺癌的預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f9e6200948d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
